Market Cap 24.23B
Revenue (ttm) 5.14B
Net Income (ttm) 1.29B
EPS (ttm) N/A
PE Ratio 15.49
Forward PE 19.28
Profit Margin 25.03%
Debt to Equity Ratio 0.00
Volume 1,516,322
Avg Vol 1,977,722
Day's Range N/A - N/A
Shares Out 202.70M
Stochastic %K 22%
Beta 0.76
Analysts Sell
Price Target $123.48

Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-...

Industry: Biotechnology
Sector: Healthcare
Phone: 302 498 6700
Address:
1801 Augustine Cut-Off, Wilmington, United States
Nomorelies
Nomorelies Aug. 4 at 7:45 PM
$INCY is running on all cylinders. https://stockstotrade.com/news/incyte-corporation-incy-news-2026_07_28/
0 · Reply
Nomorelies
Nomorelies Aug. 4 at 7:10 PM
$INCY Nice upgrades!!
0 · Reply
jdlman
jdlman Aug. 4 at 4:36 PM
$INCY $BIIB ..shut up josh brown .. always says it after the fact
1 · Reply
IN0V8
IN0V8 Aug. 3 at 4:15 PM
$INCY Buy Leerink Partners raises target price to $155 from $131
0 · Reply
AlertsAndNews
AlertsAndNews Aug. 2 at 10:17 PM
$INCY New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS "In the pivotal Phase 3 inMIND clinical trial, patients with R/R FL receiving the Minjuvi combination regimen experienced a significant improvement in progression-free survival, with a 57% reduction in the risk of disease progression, relapse or death, compared with placebo plus lenalidomide and rituximab."
0 · Reply
2_logs_higher
2_logs_higher Jul. 30 at 3:45 PM
$INCY cnbc, buy on the pullback Final Trades: Meta, ServiceNow, eBay and Incyte - CNBC https://stocks.apple.com/ArzX7BQOiQGOj50s4bZ7EhA
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 29 at 5:22 PM
Incyte Shares Retreat After Best Day In A Year Despite Opzelura EU Nod $INCY $VTI $VOO https://stocktwits.com/news/equity/markets/incyte-shares-retreat-after-best-day-in-a-year-despite-opzelura-eu-nod/cZNTReeRJT9
1 · Reply
NebulaNexus
NebulaNexus Jul. 29 at 4:38 PM
$INCY is trimming early-stage oncology programs to funnel capital into high-conviction clinical assets. A necessary pivot. The existential clock is ticking fast toward the Jakafi patent cliff. Pipeline headcount no longer impresses the tape. Execution speed and clinical validation are everything now. The core question: can upcoming candidates backfill the revenue gap before legacy cash flows dry up?
0 · Reply
Merlintrader
Merlintrader Jul. 29 at 10:39 AM
$INCY Incyte ($INCY) Stock Hub 2026: A Cash-Rich Jakafi Machine Racing Its Own 2028 Patent Cliff https://www.merlintrader.com/incyte-incy-stock-hub/
0 · Reply
Nomorelies
Nomorelies Jul. 29 at 3:27 AM
0 · Reply
Latest News on INCY
Incyte price target raised to $137 from $121 at Mizuho

2026-08-04T12:17:31.000Z - 7 hours ago

Incyte price target raised to $137 from $121 at Mizuho


Incyte price target raised to $155 from $131 at Leerink

2026-08-03T10:15:31.000Z - 1 day ago

Incyte price target raised to $155 from $131 at Leerink


Incyte price target raised to $120 from $110 at JPMorgan

2026-07-30T13:26:50.000Z - 5 days ago

Incyte price target raised to $120 from $110 at JPMorgan


Incyte price target raised to $109 from $99 at RBC Capital

2026-07-29T13:56:24.000Z - 6 days ago

Incyte price target raised to $109 from $99 at RBC Capital


Incyte price target raised to $130 from $112 at BMO Capital

2026-07-29T12:12:11.000Z - 6 days ago

Incyte price target raised to $130 from $112 at BMO Capital


Incyte price target raised to $150 from $136 at Guggenheim

2026-07-29T12:11:34.000Z - 6 days ago

Incyte price target raised to $150 from $136 at Guggenheim


Incyte says EC approves Opzelura cream for treatment of AD

2026-07-29T10:20:55.000Z - 6 days ago

Incyte says EC approves Opzelura cream for treatment of AD


Incyte price target raised to $140 from $136 at BofA

2026-07-29T10:20:20.000Z - 6 days ago

Incyte price target raised to $140 from $136 at BofA


Incyte price target raised to $139 from $134 at Barclays

2026-07-29T09:25:39.000Z - 6 days ago

Incyte price target raised to $139 from $134 at Barclays


Incyte price target raised to $145 from $123 at Stifel

2026-07-28T17:50:27.000Z - 7 days ago

Incyte price target raised to $145 from $123 at Stifel


Incyte price target raised to $120 from $107 at Oppenheimer

2026-07-28T17:45:19.000Z - 7 days ago

Incyte price target raised to $120 from $107 at Oppenheimer


Incyte Earnings Call Transcript: Q2 2026

Jul 28, 2026, 8:00 AM EDT - 7 days ago

Incyte Earnings Call Transcript: Q2 2026


Incyte Earnings release: Q2 2026

Jul 28, 2026, 8:00 AM EDT - 7 days ago

Incyte Earnings release: Q2 2026


Incyte Slides: Q2 2026

Jul 28, 2026, 8:00 AM EDT - 7 days ago

Incyte Slides: Q2 2026


Incyte Quarterly report: Q2 2026

Jul 28, 2026, 8:00 AM EDT - 7 days ago

Incyte Quarterly report: Q2 2026


Incyte reports Q2 EPS $3.09, consensus $2.15

2026-07-28T11:11:12.000Z - 7 days ago

Incyte reports Q2 EPS $3.09, consensus $2.15


Incyte price target raised to $110 from $105 at JPMorgan

2026-07-23T13:22:41.000Z - 12 days ago

Incyte price target raised to $110 from $105 at JPMorgan


Incyte to Report Second Quarter Financial Results

Jul 8, 2026, 8:00 AM EDT - 27 days ago

Incyte to Report Second Quarter Financial Results


Incyte Shares Rise on EPS Growth, Lifted Guidance, Expansion

Jul 3, 2026, 11:58 AM EDT - 4 weeks ago

Incyte Shares Rise on EPS Growth, Lifted Guidance, Expansion


Incyte Transcript: M&A announcement

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Incyte Transcript: M&A announcement


Incyte Press release: M&A announcement

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Incyte Press release: M&A announcement


Incyte Slides: M&A announcement

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Incyte Slides: M&A announcement


Incyte to Buy Vega Therapeutics For Up to $2 Billion

Jun 8, 2026, 7:34 AM EDT - 2 months ago

Incyte to Buy Vega Therapeutics For Up to $2 Billion


Incyte Proxy statement: Proxy filing

May 27, 2026, 8:00 AM EDT - 2 months ago

Incyte Proxy statement: Proxy filing


Inside Incyte's $120 Million AI For Drug Development Deal

May 20, 2026, 12:10 PM EDT - 2 months ago

Inside Incyte's $120 Million AI For Drug Development Deal


Incyte to Present at Upcoming Investor Conferences

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Incyte to Present at Upcoming Investor Conferences


Incyte Earnings Call Transcript: Q1 2026

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Incyte Earnings Call Transcript: Q1 2026


Incyte Earnings release: Q1 2026

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Incyte Earnings release: Q1 2026


Incyte Slides: Q1 2026

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Incyte Slides: Q1 2026


Incyte Quarterly report: Q1 2026

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Incyte Quarterly report: Q1 2026


Incyte Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Incyte Proxy statement: Proxy filing


Incyte Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Incyte Proxy statement: Proxy filing


Incyte to Report First Quarter Financial Results

Apr 9, 2026, 8:00 AM EDT - 4 months ago

Incyte to Report First Quarter Financial Results


Incyte Announces Executive Leadership Appointments

Mar 25, 2026, 9:00 AM EDT - 4 months ago

Incyte Announces Executive Leadership Appointments


Incyte Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 9:20 AM EDT - 5 months ago

Incyte Transcript: Leerink Global Healthcare Conference 2026


Incyte Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 10:30 AM EST - 5 months ago

Incyte Transcript: TD Cowen 46th Annual Health Care Conference


Incyte Earnings Call Transcript: Q4 2025

Feb 10, 2026, 8:00 AM EST - 6 months ago

Incyte Earnings Call Transcript: Q4 2025


Incyte Annual report: Q4 2025

Feb 10, 2026, 8:00 AM EST - 6 months ago

Incyte Annual report: Q4 2025


Incyte Earnings release: Q4 2025

Feb 10, 2026, 8:00 AM EST - 6 months ago

Incyte Earnings release: Q4 2025


Incyte Slides: Q4 2025

Feb 10, 2026, 8:00 AM EST - 6 months ago

Incyte Slides: Q4 2025


Incyte Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 11:15 AM EST - 7 months ago

Incyte Transcript: 44th Annual J.P. Morgan Healthcare Conference


Incyte Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 11:15 AM EST - 7 months ago

Incyte Slides: 44th Annual J.P. Morgan Healthcare Conference


Nomorelies
Nomorelies Aug. 4 at 7:45 PM
$INCY is running on all cylinders. https://stockstotrade.com/news/incyte-corporation-incy-news-2026_07_28/
0 · Reply
Nomorelies
Nomorelies Aug. 4 at 7:10 PM
$INCY Nice upgrades!!
0 · Reply
jdlman
jdlman Aug. 4 at 4:36 PM
$INCY $BIIB ..shut up josh brown .. always says it after the fact
1 · Reply
IN0V8
IN0V8 Aug. 3 at 4:15 PM
$INCY Buy Leerink Partners raises target price to $155 from $131
0 · Reply
AlertsAndNews
AlertsAndNews Aug. 2 at 10:17 PM
$INCY New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS "In the pivotal Phase 3 inMIND clinical trial, patients with R/R FL receiving the Minjuvi combination regimen experienced a significant improvement in progression-free survival, with a 57% reduction in the risk of disease progression, relapse or death, compared with placebo plus lenalidomide and rituximab."
0 · Reply
2_logs_higher
2_logs_higher Jul. 30 at 3:45 PM
$INCY cnbc, buy on the pullback Final Trades: Meta, ServiceNow, eBay and Incyte - CNBC https://stocks.apple.com/ArzX7BQOiQGOj50s4bZ7EhA
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 29 at 5:22 PM
Incyte Shares Retreat After Best Day In A Year Despite Opzelura EU Nod $INCY $VTI $VOO https://stocktwits.com/news/equity/markets/incyte-shares-retreat-after-best-day-in-a-year-despite-opzelura-eu-nod/cZNTReeRJT9
1 · Reply
NebulaNexus
NebulaNexus Jul. 29 at 4:38 PM
$INCY is trimming early-stage oncology programs to funnel capital into high-conviction clinical assets. A necessary pivot. The existential clock is ticking fast toward the Jakafi patent cliff. Pipeline headcount no longer impresses the tape. Execution speed and clinical validation are everything now. The core question: can upcoming candidates backfill the revenue gap before legacy cash flows dry up?
0 · Reply
Merlintrader
Merlintrader Jul. 29 at 10:39 AM
$INCY Incyte ($INCY) Stock Hub 2026: A Cash-Rich Jakafi Machine Racing Its Own 2028 Patent Cliff https://www.merlintrader.com/incyte-incy-stock-hub/
0 · Reply
Nomorelies
Nomorelies Jul. 29 at 3:27 AM
0 · Reply
BioRich
BioRich Jul. 28 at 8:29 PM
$INCY Continues to look strong.
1 · Reply
notreload_ai
notreload_ai Jul. 28 at 5:05 PM
$PRLD stock rises after $INCY discontinues INCB160058 to focus on next-gen JAK2V617F therapies, boosting its exclusive option deal. https://notreload.xyz/xy/prelude-shares-jump-as-incyte-drops-rival-jak2-drug/
1 · Reply
Nomorelies
Nomorelies Jul. 28 at 3:09 PM
$INCY Very
0 · Reply
LeoWhite961
LeoWhite961 Jul. 28 at 2:51 PM
$INCY is dropping its JAK2 V617F inhibitor INCB160058 and shifting capital toward its next-gen pipeline. That leaves room for programs like $PRLD’s PRT12396, which Incyte already has an option on from last year.
0 · Reply
Game_Day
Game_Day Jul. 28 at 2:06 PM
Currently on watch 🔥 JULY 28 $INCY $CLS $MELI $NUE
0 · Reply
Nomorelies
Nomorelies Jul. 28 at 2:04 PM
$INCY Very
0 · Reply
EarningsInsider
EarningsInsider Jul. 28 at 1:16 PM
https://www.marketbeat.com/earnings/reports/2026-7-28-incyte-co-stock/ $INCY Incyte Earnings Transcript
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jul. 28 at 12:59 PM
$SNDX Incyte released Q226 results of operations 2 hours ago. Can anyone post actual Q2 2026 Niktimvo sales? I'm at work & my empoloyer's system is noting a bad SSL certificate at Incyte so I cannot read the official press release. $INCY Thank you.
1 · Reply
Nomorelies
Nomorelies Jul. 28 at 12:08 PM
$INCY Excellent earnings report!
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Jul. 28 at 11:08 AM
$INCY Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $2.92 up 39.71% YoY • Reported revenue of $1.67B up 37.72% YoY • Incyte is raising its fiscal year 2026 total net sales guidance to $5,130 - $5,260 million, while total GAAP R&D and SG&A operating expense guidance is $4,915 - $4,995 million.
0 · Reply
Wihwnw
Wihwnw Jul. 28 at 9:25 AM
$INCY buy this before earnings if you like money. 140 soon
0 · Reply
Quantumup
Quantumup Jul. 23 at 6:44 PM
Morgan Stanley, in a broad research note earnings preview, ⬆️ $ASND to $275 from $256, reiterated (reit'd) Overweight; $DNLI to $36 from $35, reit'd Overweight; $EXEL to $53 from $50, reit'd Equal Weight; and $INCY to $104 from $103, reit'd Equal Weight, and said 2Q26 earnings should reinforce a shift from macro-driven trading toward stock-specific execution and differentiation.
0 · Reply